Skip to content

Cadrenal Therapeutics, Inc.

CVKD

CIK 0001937993 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$12.69M
−24.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$6.31
+23.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$10.91M
Q1 May 2026
Cash
$2.31M
Q1 May 2026
Total Debt
$597.07K
Q1 May 2026
Shares Outstanding
2.87M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings